Healthcare
Based on ARK ETF real-time + 13F quarterly filings
13F data may be delayed up to 90 days.
※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.
AtaiBeckley Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for mental health conditions. Their pipeline includes compounds like BPL-003, RL-007, and ELE-101, targeting conditions such as treatment-resistant depression, alcohol use disorder, and cognitive impairment associated with schizophrenia. The company is actively conducting clinical trials across the US, Germany, and Canada for these innovative therapies.
AI-generated summary. Not investment advice.